Physician profile
Than A Luu
NPI 1750548640
$25,212.51
in general payments reported to CMS, 2019-2025
56 companies · $2,651 in 2025
The $2,651 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $1,953 · 2021: $5,988 · 2022: $5,523 · 2023: $5,218 · 2024: $2,718 · 2025: $2,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,587.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,368.39 | 2019-2025 | |
| Amgen INC. | $2,092.29 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $1,911.26 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,383.40 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $1,325.06 | 2021-2025 | Vemlidy |
| Biohaven Pharmaceuticals, INC. | $1,289.80 | 2021 | |
| Novo Nordisk INC | $1,213.60 | 2020-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $1,123.90 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,033.95 | 2020-2023 | Krystexxa |
| Mannkind Corporation | $766.18 | 2020-2025 | Afrezza |
| Ironwood Pharmaceuticals, INC | $760.36 | 2019-2024 | Linzess |
| Pfizer INC. | $694.70 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.16 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $553.87 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $476.77 | 2021-2024 | Talicia, Aemcolo, Movantik |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $476.50 | 2021-2023 | Tirosint, Licart |
| Sun Pharmaceutical Industries INC. | $461.12 | 2021-2025 | Cequa, Xelpros |
| Lilly USA, LLC | $458.62 | 2019-2025 | Jardiance, Emgality |
| Ardelyx, INC. | $456.48 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.04 | 2021-2025 | Jardiance |
| Vistapharm, INC. | $430.56 | 2021 | |
| Esperion Therapeutics, INC. | $427.22 | 2022-2023 | Nexletol |
| Amarin Pharma, INC. | $412.09 | 2019-2023 | |
| Allergan, INC. | $406.12 | 2019-2021 | |
| Eisai INC. | $247.66 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $201.53 | 2022 | |
| Sunovion Pharmaceuticals INC. | $186.21 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $175.34 | 2019-2022 | |
| Alkermes, INC. | $175.21 | 2022-2023 | Lybalvi |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $125.00 | 2023 | Ocaliva |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2025 | Rexulti |
| Bard Peripheral Vascular, INC. | $95.44 | 2019 | |
| Mylan Specialty L.P. | $85.53 | 2019-2024 | Yupelri |
| Nestle Healthcare Nutrition INC. | $74.43 | 2022-2023 | |
| Alk-Abello, INC | $69.70 | 2025 | Ragwitek, Grastek, Odactra |
| Dexcom, INC. | $51.25 | 2022-2023 | Dexcom G6 Transmitter |
| Ani Pharmaceuticals, INC. | $48.89 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $48.78 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $42.61 | 2024-2025 | Cologuard Collection Kit |
| Dermira, INC. | $39.71 | 2020 | |
| Merck Sharp & Dohme LLC | $36.18 | 2019-2021 | |
| Nabriva Therapeutics, Plc | $32.47 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $22.95 | 2025 | Horizant |
| Biogen, INC. | $22.69 | 2020 | |
| Janssen Biotech, INC. | $20.84 | 2024 | Tremfya |
| Vivus LLC | $20.49 | 2023 | Pancreaze |
| Arbor Pharmaceuticals, INC. | $20.17 | 2019 | |
| Cipher Pharmaceuticals US LLC | $18.82 | 2025 | Natroba, Spinosad |
| Eyevance Pharmaceuticals LLC | $18.63 | 2021 | |
| Hikma Pharmaceuticals USA | $18.63 | 2021 | |
| Vifor Pharma, INC. | $17.20 | 2019 | |
| Genentech USA, INC. | $14.43 | 2021 | |
| Corcept Therapeutics | $13.68 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Than Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.